Comprehensive medication guide to Jublia including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Coverage varies widely; commercially insured patients with Jublia on formulary may pay $0 with the manufacturer Rx Access Program; plans that require step therapy or prior authorization may have higher cost-sharing. Medicare Part D typically does not cover Jublia.
Estimated Cash Pricing
$923–$1,055 per 4 mL bottle at retail without insurance; with the Ortho Dermatologics Rx Access Program at Walgreens or participating independents, cash-pay patients may pay as little as $75 per 4 mL bottle; GoodRx and SingleCare coupons bring the price to approximately $727–$741 per bottle at major chain pharmacies.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Jublia is the brand name for efinaconazole 10% topical solution, a prescription antifungal medication FDA-approved to treat onychomycosis (toenail fungus) caused by Trichophyton rubrum and Trichophyton mentagrophytes. It is manufactured by Ortho Dermatologics, a Bausch Health company.
Jublia was first approved by the FDA in June 2014 for adults, and its approval was expanded in April 2020 to include patients as young as 6 years old. It is one of only three topical prescription options FDA-approved for toenail onychomycosis, alongside ciclopirox nail lacquer and tavaborole (Kerydin).
Jublia comes as a clear, colorless to pale yellow solution in a white plastic bottle with an integrated flow-through brush applicator. It is available in 4 mL and 8 mL sizes. The solution is alcohol-based and flammable.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Jublia belongs to the triazole class of azole antifungals. It works by inhibiting lanosterol 14α-demethylase (CYP51), an enzyme essential for fungi to synthesize ergosterol — the key structural component of the fungal cell membrane. When ergosterol production is blocked, the fungal cell membrane becomes unstable and leaky, preventing the fungus from growing and, at sufficient concentrations, killing it entirely (fungicidal activity).
A key advantage of efinaconazole over older topical antifungals is its low binding affinity to keratin — the protein that makes up the nail. Because it doesn't bind tightly to the nail's protein structure, it remains free to penetrate deeper into the nail plate and reach the infection site more effectively than ciclopirox nail lacquer.
Systemic absorption is minimal — plasma concentrations after daily application to all 10 toenails for 28 days average just 0.67 ng/mL — which is why Jublia has no known significant drug interactions and an excellent safety profile compared to oral antifungals.
10% — topical solution
4 mL bottle with integrated flow-through brush applicator; apply once daily for 48 weeks
10% — topical solution
8 mL bottle with integrated flow-through brush applicator; apply once daily for 48 weeks
Jublia is not on the FDA drug shortage list as of 2026 — the medication is in stable supply from its manufacturer. However, many patients experience significant difficulty accessing it due to cost barriers, insurance coverage gaps, and pharmacy program restrictions that make it effectively inaccessible without assistance.
The Ortho Dermatologics Rx Access Program significantly reduces the cost to $75 per 4 mL bottle for cash-pay patients — but is only available at Walgreens and participating independent pharmacies. Most Medicare and Medicaid patients are not eligible for this program, further limiting access for elderly and low-income patients.
If you're struggling to locate Jublia at a pharmacy near you, medfinder calls pharmacies in your area to find which ones can fill your prescription, saving you the time of calling each one yourself.
Jublia is not a controlled substance and carries no DEA scheduling requirements. It can be prescribed by any licensed healthcare provider with prescriptive authority. The following specialists are common prescribers:
Dermatologists: The most common specialists for nail fungus; can perform in-office diagnostic testing (KOH prep, culture)
Podiatrists: Foot and ankle specialists who frequently treat onychomycosis; may also offer laser treatment and nail debridement
Primary Care Physicians (PCPs): Family medicine and internal medicine physicians can diagnose and treat mild-to-moderate onychomycosis
Nurse Practitioners (NPs) and Physician Assistants (PAs): Can prescribe Jublia in most states with full or supervised prescriptive authority
Jublia can also be obtained via telehealth in all 50 states since it is not a controlled substance. The manufacturer links to the Populus telemedicine platform from jubliarx.com, and many general and dermatology-specific telehealth services can also prescribe it. Telehealth is a convenient option for patients in underserved areas or those with mobility limitations.
No. Jublia (efinaconazole) is not a controlled substance and is not scheduled by the DEA. It has no abuse potential and does not require any special DEA registration or prescribing restrictions. Any licensed prescriber — including primary care physicians, nurse practitioners, physician assistants, dermatologists, and podiatrists — can prescribe Jublia without DEA restrictions.
Jublia can be refilled without special paperwork, transferred between pharmacies without restriction, and prescribed via telehealth in all 50 states. Patients do not face quantity limits, early fill restrictions, or prescription monitoring requirements associated with controlled substances.
Jublia has a favorable tolerability profile. Most side effects are localized to the application site and include:
Ingrown toenail (2.3% of patients in clinical trials)
Application site dermatitis/redness (2.2%)
Application site vesicles/blisters (1.6%)
Application site pain/burning/stinging (1.1%)
Itching and swelling at the treated nail
Severe allergic reaction: Hives, swelling, difficulty breathing — stop use and seek emergency care immediately
Significant skin irritation: Severe blistering, open sores, or worsening redness — contact your prescriber
Jublia is flammable — keep away from heat and open flames and allow to dry completely before covering. Avoid use in eyes, mouth, or vagina.
Know what you need? Skip the search.
Terbinafine (Lamisil)
Oral antifungal tablet taken once daily for 12 weeks; ~38% complete cure rate — more effective than Jublia but requires liver monitoring and has drug interactions. Generic is inexpensive (~$10–$20 for full course with discount).
Ciclopirox (Penlac)
Topical nail lacquer 8%, applied daily for 48 weeks; complete cure rate 8–11% (lower than Jublia). Requires nail debridement. Generic is very affordable (~$12–$20/month) and often covered by insurance.
Tavaborole (Kerydin)
Topical boron-based antifungal 5% solution, applied daily for 48 weeks; similar cure rates to Jublia (~15%). Generic tavaborole is now FDA-approved and may be available at lower cost.
Itraconazole (Sporanox)
Oral antifungal approved for toenail onychomycosis; ~14% complete cure rate. More drug interactions than terbinafine. Available as continuous or pulse dosing regimens.
Prefer Jublia? We can find it.
Nail Polish / Cosmetic Nail Products
moderateAvoid nail polish, gel nails, and acrylic nails during treatment. These products may block Jublia from reaching the infection site and reduce efficacy.
Other Medications (General)
minorNo clinically significant drug interactions with Jublia have been documented as of 2026 due to minimal systemic absorption. Always inform your prescriber of all medications you take.
Jublia (efinaconazole) is one of the most effective topical options available for toenail onychomycosis, with complete cure rates of 15–18% in phase 3 trials — significantly better than ciclopirox nail lacquer (8–11%) and with no known drug interactions. Its low keratin binding affinity allows superior nail penetration compared to older topical treatments.
The main challenge with Jublia is cost and access. Retail prices of $923–$1,055 per bottle and inconsistent insurance coverage create significant barriers. However, the Ortho Dermatologics Rx Access Program, Bausch Health Patient Assistance Program, GoodRx, and SingleCare coupons can substantially reduce the cost for eligible patients. Broader generic availability is expected around 2029–2030 when additional patents expire.
If you've been prescribed Jublia and are struggling to find a pharmacy that has it in stock or offers an affordable price, medfinder can call pharmacies near you to find which ones can fill your prescription — saving you hours of phone calls and helping you stay on track with your 48-week treatment.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini